Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
BHVN · Why this verdict
Why Biohaven (BHVN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.0/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Biohaven offers a large asymmetric setup — roughly 61% to the analyst consensus target with an 8.7-to-1 risk/reward ratio — backed by three consecutive earnings beats and improving price momentum; however, the company burns cash, lacks an identifiable competitive moat, and carries a 21% short interest that reflects genuine fundamental skepticism, meaning the wide upside potential must be weighed against a quality profile that remains well below investment-grade thresholds.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is negative, the business has no identified competitive moat, and the balance-sheet health score reaches only 2 out of 9 — a quality profile that sits well below the minimum investment threshold, meaning the entire thesis rests on the asymmetric price setup and pipeline execution rather than current business quality. Quality breakdown | If quality improves materially, free cash flow should turn positive on a trailing basis for at least 2 consecutive periods and the balance-sheet health score should improve above 5 out of 9. | →Stable |
| CounterFor a clinical-stage company, negative free cash flow and a minimal balance-sheet score are the expected state during the investment phase; these metrics will remain depressed until commercialization, which is by design rather than a sign of structural weakness. | ||
The stock trades roughly 61% below the analyst consensus target of $19.54, with a risk/reward ratio of approximately 8.7-to-1 in the buyer's favor — an unusually wide asymmetric setup that clears the minimum asymmetry bar despite the company's subthreshold quality profile. Price targets | Stock price closes above $19.00 within 12 months and analyst consensus targets are maintained above $18.00. | →Stable |
| CounterWide analyst-to-current-price gaps in cash-burning biotechs frequently reflect speculative price target setting rather than near-term earnings power; a 61% discount to target can persist or widen if pipeline milestones disappoint or capital needs increase. | ||
After a miss at the oldest reported quarter, the company has beaten consensus estimates in each of the three most recent consecutive periods, with the latest beat registering nearly 10% above estimate — a pattern suggesting the gap between management guidance and actual results is narrowing favorably. Earnings | Beat streak extends to 5 or more consecutive quarters with no single quarter missing by more than 2%. | →Stable |
| CounterThree consecutive beats in a development-stage company may reflect analysts consistently over-estimating costs or under-estimating non-cash adjustments rather than genuine operational outperformance; the pattern may not persist if the comparison base normalizes. | ||
With RSI at 63, a bullish MACD, rising volume accumulation, and the stock above its 200-day moving average, the technical setup is consistent with a momentum continuation; a prior moving average crossover warning has begun recovering, with the momentum reading now above the level at which the signal is considered stabilizing rather than deteriorating. Momentum breakdown | RSI stays above 55 and the stock holds above its 200-day moving average for at least 2 more consecutive quarters. | →Stable |
| CounterMomentum readings above 60 at a prior crossover recovery point can be unstable; if the recovery stalls before the longer-term average slope turns definitively positive, the near-term technical pattern may reverse rather than extend. | ||
Short interest at 21% of shares — described as justified given the quality profile — reflects significant informed conviction on the short side; this concentration represents both a downside risk if the short thesis is correct and a potential source of upside acceleration if positive news forces covering. Risk breakdown | If the short thesis breaks down, short interest should decline from 21% toward 10% or below as covering pressure builds over the following 2 quarters. | →Stable |
| CounterHigh short interest that is justified by the quality profile may represent stable, long-term positions rather than short-term speculative trades; covering that compresses the ratio may not occur until fundamental quality metrics show a durable positive inflection. | ||
Free cash flow is negative, the business has no identified competitive moat, and the balance-sheet health score reaches only 2 out of 9 — a quality profile that sits well below the minimum investment threshold, meaning the entire thesis rests on the asymmetric price setup and pipeline execution rather than current business quality.
→StableQuality breakdown
- Expectation
- If quality improves materially, free cash flow should turn positive on a trailing basis for at least 2 consecutive periods and the balance-sheet health score should improve above 5 out of 9.
CounterFor a clinical-stage company, negative free cash flow and a minimal balance-sheet score are the expected state during the investment phase; these metrics will remain depressed until commercialization, which is by design rather than a sign of structural weakness.
The stock trades roughly 61% below the analyst consensus target of $19.54, with a risk/reward ratio of approximately 8.7-to-1 in the buyer's favor — an unusually wide asymmetric setup that clears the minimum asymmetry bar despite the company's subthreshold quality profile.
→StablePrice targets
- Expectation
- Stock price closes above $19.00 within 12 months and analyst consensus targets are maintained above $18.00.
CounterWide analyst-to-current-price gaps in cash-burning biotechs frequently reflect speculative price target setting rather than near-term earnings power; a 61% discount to target can persist or widen if pipeline milestones disappoint or capital needs increase.
After a miss at the oldest reported quarter, the company has beaten consensus estimates in each of the three most recent consecutive periods, with the latest beat registering nearly 10% above estimate — a pattern suggesting the gap between management guidance and actual results is narrowing favorably.
→StableEarnings
- Expectation
- Beat streak extends to 5 or more consecutive quarters with no single quarter missing by more than 2%.
CounterThree consecutive beats in a development-stage company may reflect analysts consistently over-estimating costs or under-estimating non-cash adjustments rather than genuine operational outperformance; the pattern may not persist if the comparison base normalizes.
With RSI at 63, a bullish MACD, rising volume accumulation, and the stock above its 200-day moving average, the technical setup is consistent with a momentum continuation; a prior moving average crossover warning has begun recovering, with the momentum reading now above the level at which the signal is considered stabilizing rather than deteriorating.
→StableMomentum breakdown
- Expectation
- RSI stays above 55 and the stock holds above its 200-day moving average for at least 2 more consecutive quarters.
CounterMomentum readings above 60 at a prior crossover recovery point can be unstable; if the recovery stalls before the longer-term average slope turns definitively positive, the near-term technical pattern may reverse rather than extend.
Short interest at 21% of shares — described as justified given the quality profile — reflects significant informed conviction on the short side; this concentration represents both a downside risk if the short thesis is correct and a potential source of upside acceleration if positive news forces covering.
→StableRisk breakdown
- Expectation
- If the short thesis breaks down, short interest should decline from 21% toward 10% or below as covering pressure builds over the following 2 quarters.
CounterHigh short interest that is justified by the quality profile may represent stable, long-term positions rather than short-term speculative trades; covering that compresses the ratio may not occur until fundamental quality metrics show a durable positive inflection.
Per-dimension breakdown
Quality
1.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.6 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 0.0 |
- ▸Overbought (RSI 78)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 78 (late-cycle distribution risk)
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.4 |
| Price target | 9.2 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 41%
Insider
5.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.7 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
2.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 5.0 |
Technical
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.5 |
| support resistance | 0.7 |
| 52w position | 6.6 |
Risk (lower is worse)
0.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.4 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 0.0 |
| debt equity | 2.8 |
- ▸High short interest justified: 21%
- ▸Elevated put/call: 3.24
- ▸High IV: 103%
- ▸Above max pain $4
Catalyst
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 4.5 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.3>=5.5
- ASYMMETRY:1.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:46d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- DEATH_CROSS:momentum=6.3>=5.0 recovering
Reward-to-Risk
1.79
Upside
+26.9%
Downside
15.0%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 78
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 3.31>1.3, MCap $2.3B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 7.3, and Momentum at 6.3; the weakest are Risk (lower is worse) at 0.9, Quality at 1.4, and Peer rank at 2.5. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 1.79 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The stock trades roughly 61% below the analyst consensus target of $19.54, with a risk/reward ratio of approximately 8.7-to-1 in the buyer's favor — an unusually wide asymmetric setup that clears the minimum asymmetry bar despite the company's subthreshold quality profile.
Trip ifAnalyst consensus price target is revised below $15.00, reducing implied upside from current levels to less than 20%.
- P2After a miss at the oldest reported quarter, the company has beaten consensus estimates in each of the three most recent consecutive periods, with the latest beat registering nearly 10% above estimate — a pattern suggesting the gap between management guidance and actual results is narrowing favorably.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, breaking the beat streak.
- P3With RSI at 63, a bullish MACD, rising volume accumulation, and the stock above its 200-day moving average, the technical setup is consistent with a momentum continuation; a prior moving average crossover warning has begun recovering, with the momentum reading now above the level at which the signal is considered stabilizing rather than deteriorating.
Trip ifStock falls below its 200-day moving average and RSI drops below 45 for 4 consecutive weeks.
- P4Free cash flow is negative, the business has no identified competitive moat, and the balance-sheet health score reaches only 2 out of 9 — a quality profile that sits well below the minimum investment threshold, meaning the entire thesis rests on the asymmetric price setup and pipeline execution rather than current business quality.
Trip ifFree cash flow rises above $0 on a trailing-twelve-month basis for 2 consecutive reported periods, indicating the cash-burn quality concern has resolved.
- P5Short interest at 21% of shares — described as justified given the quality profile — reflects significant informed conviction on the short side; this concentration represents both a downside risk if the short thesis is correct and a potential source of upside acceleration if positive news forces covering.
Trip ifShort interest falls below 10% of shares outstanding for 2 consecutive monthly reporting periods.